News & Updates
Oral presentation highlights EPI-321 effects on multiple clinically relevant markers – Excerpt from the Press Release: – Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The data were shared in…
Read More
Study is the Second Clinical Human Trial Using Mobetron with Electron Excerpt from the Press Release: SUNNYVALE, Calif.–(BUSINESS WIRE)–IntraOp Medical Corporation announced the world’s first Phase II Electron FLASH Trial. It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC). It is the second…
Read More
Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases Excerpt from the Press Release: NEWARK, Calif., May 12, 2023 /PRNewswire/ — Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on…
Read More
May 20th celebrates International Clinical Trials Day, as a time to give thanks and support to all the exceptionally hard-working clinical research pros out there! Their work is like putting together a massive puzzle that maps out the terrain of public health and medicine. We set aside May 20th each year to tip our hats…
Read More
Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter patent for brilaroxazine-lipogel and a separate patent for use in the treatment of psoriasis Excerpt from the Press Release: CUPERTINO, Calif., May 11, 2023…
Read More
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Excerpt from the Press Release: Carlsbad, CA, May 11, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced…
Read More
Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition Excerpt from the Press Release: WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous…
Read More
OICR announces support for five projects through its Cancer Therapeutics Innovation Pipeline (CTIP) Excerpt from the Press Release: Ontario research teams investigating new ways to treat cancer are taking the crucial next steps to bring their discoveries to patients thanks to support from the Ontario Institute for Cancer Research (OICR). OICR announced it is funding…
Read More
Excerpt from the Press Release: PALO ALTO, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced complete enrollment in…
Read More
Excerpt from the Press Release: SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) — Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed patient enrollment ahead of schedule in its Phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?